Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 17:7:212516.
doi: 10.7573/dic.212516. eCollection 2018.

Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

Daniel I G Cubero  1 , Beatrice Martinez Zugaib Abdalla  2 , Jean Schoueri  3 , Fabio Iazetti Lopes  3 , Karine Corcione Turke  2 , Jose Guzman  2 , Auro Del Giglio  1 , Carlos D'Apparecida Santos Machado Filho  2 , Vanessa Salzano  2 , Dolores Gonzalez Fabra  2
Affiliations
Review

Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

Daniel I G Cubero et al. Drugs Context. .

Abstract

Background: Currently, molecularly targeted drugs are part of the therapeutic arsenal for the treatment of many neoplasms and are responsible for improvements in the quality of life and survival of patients. Although they act on proteins and components within biochemical pathways that are expressed to a greater extent in neoplastic cells, these drugs can also interfere with the activity of normal cells.

Scope: This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.

Findings: The use of these drugs causes side effects, and the skin is one of the most commonly affected organs. In this literature review, we discuss the adverse cutaneous effects caused by molecularly targeted drugs.

Conclusion: The identification of these reactions is important to both dermatologists and oncologists so that they properly diagnose the reaction and administer adequate treatment, which would allow greater adherence to the oncological treatment and improve patients' quality of life.

Keywords: adverse reactions; chemotherapy; dermatology; drug-related side effects; immunotherapy; oncology; skin; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2018/06/dic.212516-COI.pdf

Figures

Figure 1
Figure 1. EGFR pathway diagram
EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; mTOR, mammalian target of rapamycin; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase.
See this image and copyright information in PMC

References

    1. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59(2):111–137. doi: 10.3322/caac.20003. - DOI - PubMed
    1. Lacouture ME. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients. Hoboken, NJ: Wiley-Blackwell; Jan, 2014.
    1. Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy. J Am Acad Dermatol. 2014;71(2):217.e1–217.e11. doi: 10.1016/j.jaad.2014.04.013. quiz 227–228. - DOI - PubMed
    1. Payne AS, Savarese DM. Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy. In: Post TW, editor. Up To Date. Waltham, MA: UpToDate Inc; [Accessed October 7, 2017]. http://www.uptodate.com.
    1. Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother. 2009;43(10):1658–1666. doi: 10.1345/aph.1M241. - DOI - PubMed